Myasthenia Gravis

The findings from among patients with myasthenia gravis (MG) could point the way to a potential new drug target, the authors said.

With most previous studies on ocular myasthenia gravis stemming from investigations the neurology field, the present investigators came to their conclusion via neuro-ophthalmic analysis.

A real-world study of health care resource utilization (HCRU) in patients with myasthenia gravis on second-line therapy identified the factors that led to increased financial burdens.

The researchers note that this finding adds valuable insight for individualized treatment decisions in scenarios where the role of thymectomy is not fully clear.

The systemic review and meta-analysis, believe the researchers, is the first of its kind to characterize the prevalence of depression among these patients.

The researchers hypothesize that SARS-CoV-2 infection may have triggered thymic inflammation, spearheading initial expression of muscle-like epitopes and T-cell dysregulation.